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Background:
Erlotinib is a potent first-generation inhibitor of EGFR, and is an established first-line therapy for patients with NSCLC positive for exon 19 deletions or exon 21 mutations (1) . Erlotinib blocks EGFR kinase activity, suppressing downstream signaling via multiple intermediates including the mitogen-activated protein kinase and phosphatidylinositol-3-kinase -AKT pathways (2) . These signaling pathways are activated by additional receptors including IGF-1R (3) . IGF-1R is expressed almost ubiquitously by normal tissues, is activated by ligands IGF-1 and -2, and is required for embryonic development and postnatal growth (4, 5) . IGF-1R has become a target for cancer therapy, because components of the IGF axis are often aberrantly expressed in cancers, and IGF pathway activation promotes tumorigenesis and metastasis (4, 6) . Furthermore, IGF-1R overexpression is associated with adverse survival in several tumor types (7) (8) (9) (10) . Cancers also express a variant form of the insulin receptor (INSR-A) that is activated by IGF-2 and insulin to drive proliferation and cell survival (11) . INSR-A signaling can compensate for IGF-1R inhibition (12) , and co-inhibition of IGF-1R and INSR may provide enhanced anti-tumor activity (13, 14) .
Linsitinib (OSI-906) is a potent, orally bioavailable dual IGF-1R and INSR tyrosine kinase inhibitor (TKI) with anti-proliferative effects in a variety of tumor cell lines, and anti-tumor activity in an IGF-1R-driven xenograft model (15, 16) . Preliminary anti-tumor activity has been reported for single-agent linsitinib in patients with solid tumors including partial responses (PRs) in melanoma and adrenocortical carcinoma (17) (18) (19) . Combined IGF-1R/INSR and EGFR blockade may enhance inhibition of common downstream signaling pathways, and suppress resistance to single-receptor blockade (6, 14, 20) .
Preclinical data indicate that IGF-1R mediates acquired resistance to erlotinib in lung cancers with wild type EGFR, and combined inhibition of IGF-1R/INSR and EGFR results in supra-additive inhibition of tumor growth in vitro and in vivo in NSCLC, breast, pancreatic and colorectal cancer (CRC) (21) (22) (23) (24) (25) . Author Manuscript Published OnlineFirst on February 1, 2016; DOI: 10.1158/1078-0432.CCR- Furthermore, in a recent CRC xenograft study, erlotinib-resistant tumors had marked IGF-2 overexpression, and were sensitized to EGFR inhibition by a small-molecule IGF-1R TKI (26) .
In the current study, linsitinib was combined with erlotinib in patients with advanced solid tumors. The primary objectives were to determine the maximum tolerated dose (MTD) and define the recommended phase II dose (RP2D) of linsitinib plus erlotinib. Secondary objectives were to evaluate safety, preliminary antitumor activity, PK, and pharmacodynamic profiles.
Patients and Methods: Patient population
Male and female patients ≥18 years were eligible if they had a histologically or cytologically confirmed advanced solid tumor and Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2. Patients were required to be nonsmokers for ≥3 months prior to study entry, have a negative urine cotinine test, and have adequate cardiac, hematopoietic, hepatic, and renal function, including corrected QT interval (QTc) ≤450 ms with no concurrent use of drugs that may prolong QTc, fasting glucose ≤125 mg/dL (7.0 mmol/L), and blood ketones equal to or below the upper limit of normal. Patients were excluded for a history of diabetes mellitus or significant heart disease, prior EGFR or IGF-1R inhibitor therapy, or use ≤14 days of strong or moderate CYP3A4 or CYP1A2 inhibitors/inducers, proton pump inhibitors or drugs with an established risk of causing QTc prolongation. Prior anti-cancer therapy was permissible if chemotherapy was discontinued 3 weeks prior to the study (4 weeks for carboplatin or investigational agents, 6 weeks for nitrosoureas and mitomycin-C), hormonal therapy was discontinued prior to trial therapy, and patients had recovered from any acute radiation toxicity and recent surgery. For inclusion in the advanced NSCLC expansion cohort, patients required measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (27) 
Study design
This was a multi-center, phase I, open label study of linsitinib plus erlotinib in patients with advanced solid tumors (NCT00739453). The primary objectives were to determine the MTD and establish the RP2D of linsitinib plus erlotinib. Secondary study objectives included safety, PK and pharmacodynamic profiles, antitumor activity, and potential correlation between exploratory biomarkers and clinical outcomes in an expansion cohort of patients with advanced NSCLC.
A standard '3 + 3' dose escalation design was used in 3 oral linsitinib dose schedules of 21-day treatment cycles. In the S1 intermittent schedule, linsitinib was administered on days 1-3 every 7 days, starting at 50 mg once daily (QD), escalating to 600 mg QD. Schedule 2 (S2) continuous dosing of linsitinib started at 50 mg QD, escalating to 400 mg, and in schedule 3 (S3) twice daily (BID) continuous schedule, linsitinib was administered at 100 or 150 mg BID. Oral erlotinib was administered at 100 or 150 mg QD on days 2-21 of the first cycle and days 1-21 for the remaining cycles. Initiation of schedules S1-3 occurred consecutively with the next schedule starting following clinically-significant related grade ≥2 toxicity in the previous schedule, or achievement of ≥2 dose levels in the previous schedule without dose-limiting toxicity (DLT). Following completion of S1-3, a NSCLC expansion cohort was initiated, administering linsitinib 150 mg BID, the established monotherapy RP2D (18) , starting at day 1, and erlotinib at 150 mg QD starting at day 8 of cycle 1.
Research. Toxicity was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) v3.0 and DLTs were defined as clinically significant toxicity considered to be related to study drug and occurring during the initial cycle. DLTs included standard hematologic (grade 4 neutropenia or thrombocytopenia, grade ≥3 febrile neutropenia, documented grade ≥3 infection with grade ≥3 neutropenia) and non-hematologic criteria (any grade ≥3 toxicity excluding fatigue, γ-glutamyl transferase elevation, nausea or rash). Additional DLTs included glucose intolerance, defined as grade 3 symptoms of hyperglycemia accompanied by grade 2 hyperglycemia (fasting glucose >160 mg/dL or 8.9 mmol/L), grade 3 fasting glucose >250 mg/dL (13.9 mmol/L), grade 3 electrolyte abnormalities due to glucose intolerance, positive ketones (above the upper limit of normal), or grade 4 hyperglycemia (glucose >500 mg/dL or 27.8 mmol/L). Also included as DLTs were drug-related toxicity of any severity causing inability to begin a second cycle by day 36 in any schedule, or to complete the first cycle in S1, or requiring interruption of dosing ≥5 continuous days in S2 and S3. DLTs were assessed during the initial 21-day cycle with final assessment on day 22, along with the need for subsequent dose interruptions, delays, or occurrence of cumulative toxicity. DLTs were assessed in ≥3 patients per cohort and patients had to complete a full cycle before the next dose level could be opened. Following a DLT, 3 additional patients were treated at that dose level, up to 6 per cohort. The DLT population comprised patients in S1 who did not miss >3 days of linsitinib and >5 days of erlotinib during the initial cycle, and patients in S2 and S3 who did not miss >5 days dosing of either drug during the initial cycle. The MTD was defined as the highest dose at which no more than 1 of 6 patients experienced a DLT (ie, the dose level below that which induced a DLT in ≥33% of patients). The NSCLC expansion cohort was enrolled using dosing based on the S3 schedule, and clinical safety and PK data from the twice-daily monotherapy study (18) .
Research. 
Safety and efficacy
AEs were recorded from the signing of informed consent to 30 days after the final dose of study drug. Laboratory data included hematology (full blood count including hemoglobin, hematocrit, platelets and reticulocyte counts) and biochemistry data: blood glucose, insulin, lactate, blood ketones, blood urea nitrogen, creatinine, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, alkaline phosphatase, total protein, electrolytes, γ-glutamyl transferase, lactate dehydrogenase, lipase, total cholesterol, and triglycerides. During the initial cycle, blood glucose was monitored twice daily by patients using a home glucometer. Safety was also monitored by physical examination and electrocardiogram pre-dose on day 1, post-dose on days 1, 2, 8, and 15 of the first cycle, pre-and post-dose on day 22, pre-dose on day 1 of every subsequent cycle, and at last study visit.
Measurable disease was required only for enrollment of the expansion cohort, but disease status, evaluated by RECIST, was assessed in all patients every 6-8 weeks by physical and radiological examination. Patients were evaluable for efficacy if they had measurable disease according to RECIST, received at least 21 days of therapy and underwent disease re-evaluation.
Pharmacokinetics
For patients on schedules S1-S3, plasma samples were collected on day 1 pre-dosing of dose escalation or NSCLC expansion phases using standard polymerase chain reaction (PCR), ICE-COLD-PCR™ and SURVEYOR® and WAVE® HS System analysis followed by Sanger dideoxy sequencing (Transgenomic, Omaha, NE) as described (18) .
Results
Ninety-five patients were enrolled at 4 sites in the United States and United Kingdom, including 44 in S1, 24 in S2, 12 in S3 and 15 in the NSCLC expansion cohort. Patient demographics and baseline characteristics are shown in Table 1 . Patients were aged 20-85 years and 98% had an ECOG PS of 0 or 1.
The largest proportion of patients presented with NSCLC (34%) followed by prostate cancer (5%), pancreatic cancer (4%), and CRC (4%). Approximately 50% of patients had received at least 3 previous lines of treatment (Table 1) . Of the 95 patients, 91 were treated and included in the safety and PK populations, 67 in the DLT population and 75 in the efficacy population. Ninety patients discontinued the study, 69 (77%) due to disease progression, 13 (14%) due to an AE, and 8 (9%) by patient request.
Dose escalation and MTD
In the dose escalation phase, 7 patients experienced 10 DLTs (4 in S1, 2 in S2, and 1 in S3), including QTc prolongation, hyperglycemia, elevated liver function tests and anorexia (Table 2A ). All DLTs were considered related to linsitinib alone or the linsitinib/erlotinib combination. MTDs were established for the intermittent S1 schedule as 450 mg linsitinib QD days 1-3 every 7 days and 150 mg erlotinib QD, and for the continuous S2 schedule as 400 mg linsitinib QD and 100 mg erlotinib QD. The S3 schedule did not achieve ≥33% of patients with DLTs; dose escalation was not pursued further because the RP2D for linsitinib as monotherapy was established at 150 mg linsitinib BID in a separate clinical study (18) , and erlotinib was already at the approved dose. This dose combination was chosen as the RP2D for the expansion cohort due to the acceptable safety profile in the S3 schedule (no AEs of 
Safety
Of the 91 treated patients, 89/91 (98%) experienced treatment-related AEs, of maximum severity grade 1 in 15 patients (16%), grade 2 in 47 (52%), grade 3 in 24 (26%), and grade 4 in 3 (3%). The commonest treatment-emergent AEs across all cohorts were drug eruption (84%), diarrhea (73%), fatigue (68%), nausea (58%), and vomiting (40%), with frequencies similar across the dosing schedules except that vomiting occurred more often in S3 (67% compared with 32-40% in other cohorts; Table   2B ). Fatigue was more common in S1 (72%) and S2 (75%) compared with S3 (58%) and the expansion cohort (53%), and was the only treatment-emergent AE to occur at grade ≥3 in ≥5% of patients, observed only in S1 and S2. AE causality was determined by investigator judgment based on known AEs of erlotinib and linsitinib. AEs related specifically to linsitinib occurred in 43% of patients, including 48% in S1, 33% in S2, 25% in S3, and 60% in the expansion cohort. The most common were fatigue (12%), nausea (11%), vomiting (8%), and prolonged QTc interval (8%); all the linsitinib-related AEs in S1 and S2 occurred in patients receiving ≥300 mg linsitinib. Erlotinib-related AEs were reported in 84% of patients and the most common were drug eruption (74%), dry skin (26%), pruritus (26%), and diarrhea (26%). AEs attributed to both linsitinib and erlotinib were reported in 82% of patients; the most common were fatigue (45%), diarrhea (43%), nausea (37%), and anorexia (20%).
Serious AEs (SAEs) were reported in 42% including 52% of patients in S1, 21% in S2, 42% in S3, and 47% in the expansion cohort, with nausea (7%) and vomiting (7%) the most frequent drug-related 
SAEs. Treatment-related SAEs occurred in 13 patients (14%) including 10/40 (25%) patients in S1 and 3/15 (20%) in the expansion cohort. These included SAEs related to both linsitinib and erlotinib: fatigue (1 patient), malaise (1), nausea (1), vomiting (3), diarrhea (2), anemia (1), increased ALT (2), increased AST (1), acute renal failure (1), QTc prolongation (1) and gastrointestinal perforation (1) . SAEs attributed to erlotinib alone were rash (1), pneumonitis (1), gastrointestinal perforation (1), gastrointestinal hemorrhage (1). One SAE was considered to be related to linsitinib alone: grade 3 hyperglycemia occurred in 2 patients in S1 and 1 patient in the expansion cohort. AEs led to study discontinuation for 13 patients, including 6 (15%) in S1, 2(8%) in S2, 3 (25%) in S3, and 2 (13%) in the expansion cohort. Of those, 3 patients had an event related to erlotinib only, 1 to linsitinib only (prolonged QTc interval), and 5 to the combination. Nine patients died within 30 days of the last linsitinib dose, due to underlying disease (7 patients), pneumonia (1), or dehydration following a suicide attempt (1).
AEs of special interest to linsitinib include hyperglycemia, hypoglycemia, and prolonged QTc interval. Linsitinib-related hyperglycemia occurred in 5 patients (5%) including 3 in S1 and 2 in the expansion cohort, at grade 3 (3 cases) and grade 2 (2). All instances of hyperglycemia responded to temporary (3-5 days) interruption of linsitinib, followed by reduction of linsitinib to the next lowest dose. Glucometer readings indicated grade 3-4 hypoglycemia in 8 patients, including 2 patients treated on schedule S3 at the RP2D. Only 1 of these low readings, in an S1 patient, was accompanied by simultaneous serum glucose measurement showing low glucose (grade 2). Prolonged QTc occurred in 9 patients (10%; see Table 2B ): grade 1 in 2 patients (S1: 450/100 mg and S2: 300/150 mg), grade 2 in 5 patients (S1: 400/150 mg, 1 case, and 450/150 mg, 2 cases; S2: 1 case at 400/150 mg; NSCLC expansion cohort: 1 case at 150/150 mg), and grade 3 in 2 patients (S1: 450/150 mg and S2: 400/150 mg); 7 of these were attributed to linsitinib. It was unclear whether there was a relationship between occurrence of QTc prolongation and peak circulating drug concentrations, however, in another study QTc 
prolongation was associated with peak concentrations of linsitinib at the 600 mg dose (unpublished data). Figure 1A shows median plasma linsitinib levels in patients treated at S1, S2 or S3 MTDs. Levels peaked at 4 hours, declined over 24 hours in the S1 and S2 cohorts to near or below the 400 ng/mL (~1 μM) level associated with preclinical activity (15, 16) , and were maintained above this threshold in the twice daily S3 cohort. Profiles were similar following day 1 (linsitinib alone) and day 2 (combination) dosing. Linsitinib C max and AUC from time zero to infinity increased in a dose-proportional manner in a comparison of dose-normalized parameters in S1 and S2. In the NSCLC expansion cohort, where linsitinib was dosed from day 1 and erlotinib from day 8, linsitinib PK parameters were similar after dosing 150 mg linsitinib BID as a single agent (day 7) and in combination with 150 mg erlotinib QD (days 8 and 22; Table 3, Figure 1B ). These data suggest that there was no significant drug-drug interaction effect on linsitinib PK parameters. Furthermore, analysis of erlotinib and OSI-420 PK after dosing the linsitinib/erlotinib combination (Table 3, Figure 1 ) showed parameters similar to previously published data after erlotinib monotherapy (28, 29) , suggesting that linsitinib did not alter the PK of erlotinib.
Pharmacokinetic analysis

Efficacy
Of 75 patients evaluable for efficacy, none achieved complete response, 5 (7%) achieved PR, and 33 (44%) had stable disease (SD) for a minimum of 6 weeks (Table 4A ). The 5 patients achieving PR included 2 on the intermittent S1 schedule (NSCLC, rectal cancer), 1 on S2 (spinal chordoma) and 2 with NSCLC treated at the RP2D in the expansion cohort. Disease control rate (CR + PR + SD) occurred in 10 patients in S1 (32%), 13 patients in S2 (68%), 6 patients in S3 (55%), and 9 patients in the expansion cohort (64%). Duration on study by treatment schedule is shown in Figure 2A . The median (mean ± standard error) duration of treatment was 6 (12 ± 3) weeks in S1, 10 (23 ± 9) weeks in S2, 7 (17 ± 7)
Research. In total, the study recruited 31 NSCLC patients including 22 with adenocarcinoma and 9 with non-adenocarcinoma histology (4 squamous, 2 papillary, 1 mixed adenosquamous, 2 unclassified). Of the patients with adenocarcinoma, 2 (9%) achieved PR, 1 in S1 and 1 in the expansion cohort, 7 (32%) SD and 13 (59%) PD. Equivalent figures for the non-adenocarcinoma cases were 1 (11%) PR in a patient treated on the expansion cohort, 5 (56%) SD, 3 (33%) PD. The 15 NSCLC patients treated in the expansion cohort at the RP2D included 11 with adenocarcinoma (1 with PR, 5 with SD, 5 with PD) and 4 with non-adenocarcinoma histology (1 PR, 2 SD, 1 PD). Figure 2B shows chest computed tomography (CT) images from a patient with squamous NSCLC who achieved PR during treatment at the RP2D.
Pharmacodynamic analysis
PBMCs from 9 patients were analyzed for IGF-1R and INSR phosphorylation, including 3 patients in S1 (2 at 150mg, 1 at 450 mg), 5 in S2 (2 at 300 mg, 3 at 400 mg) and 1 in S3 (150 mg BID). Two cases showed no detectable signal; data for the remaining 7 cases are shown in Figure 2C . IGF-1R/INSR phosphorylation was substantially inhibited 2-24 hours after the first dose. Later time points showed fluctuating receptor inhibition in patients on the intermittent S1 schedule, and persisting receptor inhibition in patients treated with ≥300 mg linsitinib daily in S2 and S3. However, there was considerable variation between patients, some showing recovery in pre-dose samples taken on days 3, 15 and 23. Figure 1B , and 1 with rectal cancer. EGFR exon 19 mutations were detected in ctDNA of 2 further NSCLC patients, both treated at the RP2D in the NSCLC expansion cohort. Neither responded to trial therapy; both cases had received prior erlotinib and also harbored the exon 20 T790M mutation associated with erlotinib resistance (30, 31) . A CRC patient with brief SD as best response had ctDNA mutations in both PIK3CA (E542K) and KRAS (G12V). KRAS codon 12 mutations were also detected in the plasma and tumor DNA of 2 NSCLC patients, both with SD as best response (duration 6 weeks, 30 weeks).
Discussion
This study demonstrates that combination treatment with linsitinib and erlotinib has acceptable tolerability, with no PK evidence of significant drug-drug interaction, and detectable but modest antitumor activity in unselected patients. MTDs were defined as 450 mg linsitinib QD days 1-3 every 7 days with 150 mg erlotinib QD in the S1 schedule, and 400 mg linsitinib QD with 100 mg erlotinib QD for the S2 once-daily continuous schedule. This compares with linsitinib MTDs defined in monotherapy studies of 600 mg linsitinib for intermittent dosing and 400 mg QD for continuous once-daily dosing (17, 18) . Based on data from this trial and the monotherapy study, and the finding that linsitinib has a short half-life (5 hours; 18), twice daily dosing is required to achieve continuous inhibition of IGF1R and IR, with RP2D for the combination of 150 mg linsitinib BID and 150 mg erlotinib QD. In all, 64 patients in the S1 and S2 cohorts received total linsitinib doses above the RP2D (300mg/day), reflecting the fact that recruitment was conducted in parallel with the monotherapy studies (17, 18) , and information on monotherapy RP2D was available only towards the end of the current trial.
The commonest linsitinib-related AEs were fatigue, nausea, vomiting and QTc prolongation, similar to those reported in monotherapy studies (17) (18) (19) . The three dosing schedules had similar toxicities, except that linsitinib treatment-related SAEs occurred in 10/40 (25%) patients in S1 but not in S2 or S3, suggesting that continuous linsitinib dosing may be better tolerated, perhaps reflecting metabolic changes associated with intermittent IGF-1R/INSR blockade. Specific AEs in this study reflected toxicities observed in monotherapy studies of linsitinib and IGF-1R antibodies, including hyperglycemia and abnormal liver function (17) (18) (19) (32) (33) (34) (35) (36) , suggesting that these are class effects of IGF-1R inhibition. In contrast thrombocytopenia and neutropenia were reported in studies of IGF-1R antibodies (37) but were not observed with linsitinib. QTc prolongation was dose-limiting in this trial, as with other small molecule drugs, is not considered to be mechanism-based (38), and was not observed in IGF-1R antibody trials (33-37).
Recent reviews have discussed the limited clinical activity of single-agent IGF-1R inhibition, and the degree of IGF-1R/INSR blockade achieved by IGF axis inhibitors of different classes (5, 6, 14) . IGF-1R antibodies downregulate IGF-1Rs, while IGF-1R TKIs suppress receptor activity without influencing IGF-1R expression (6) . IGF-1R antibodies demonstrated single-agent activity in soft tissue sarcomas, Ewing and thymic tumors, but not in common cancers (6, 32, 33, 36, 39 to report clinically, and as monotherapy induced partial responses in adrenocortical carcinoma and melanoma (17, 18) . In a randomized phase III trial in adrenocortical carcinoma, 3/90 patients on the linsitinib arm experienced durable PR, with no difference in overall survival between linsitinib and placebo arms (19) . Linsitinib has also been combined with everolimus in metastatic CRC, with no evidence of clinical activity (40) .
In light of these concerns about efficacy, PK and pharmacodynamic analyses tested whether IGF- with SD as best response (43) . Also in NSCLC, R1507 was tolerable with erlotinib; there was no progression-free survival or overall survival advantage over erlotinib alone in unselected patients, but the 12-week progression-free survival rate in patients with KRAS mutant tumors was 36% for R1507 vs 0% on the placebo arm (44) . In the current study, combination treatment with linsitinib and erlotinib showed preliminary evidence of antitumor activity, and durable objective responses occurred in patients on all three linsitinib schedules, with 28/91 (31%) patients on study for >12 weeks.
We did not attempt to quantify IGF-1R or EGFR in the tumours of trial subjects, since these parameters have not been shown to be useful predictive biomarkers (6) . In a subset of patients we were able to analyze ctDNA and archival tumor DNA, to investigate correlations between tumor-derived mutations and response. Functionally significant KRAS mutations were detected in 2 NSCLC patients, both of whom had SD, one durable. There are conflicting reports of the association of RAS mutation and/or RAS-MEK-ERK pathway activation with response to IGF-1R inhibition, some (including the clinical R1507 study highlighted above) supporting association with sensitivity to IGF-1R inhibition (44) (45) (46) , and others with resistance (47, 48) . EGFR mutations were detected in ctDNA of 3 of 30 NSCLC cases, consistent with the published incidence (10-13%) of NSCLC EGFR mutations (49) . The clinical response in a patient with EGFR exon 19-deleted NSCLC (Table 4B) is consistent with the association between this mutation and erlotinib sensitivity, and the additional 'gatekeeper' EGFR T790M mutation, detected in 2 non-responders here, with erlotinib resistance (30, 31, 50) . The presence of only 2 informative cases harboring EGFR T790M is insufficient to assess activity of the linsitinib/erlotinib combination in this setting. However, there was evidence of clinical activity in tumors unlikely to respond to single-agent erlotinib, including durable partial responses in EGFR wild-type squamous lung cancer and spinal chordoma. Further analysis of the latter will be reported separately. Tables   Table 1. Baseline demographic 
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